Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>SJB3-019A

SJB3-019A

Catalog No.GC13401

SJB3-019A est un puissant et nouvel inhibiteur de l'USP1, 5 fois plus puissant que SJB2-043 pour favoriser la dégradation et la cytotoxicité de l'ID1 dans les cellules K562 avec une IC50 de 0,0781 μM.

Products are for research use only. Not for human use. We do not sell to patients.

SJB3-019A Chemical Structure

Cas No.: 2070015-29-9

Taille Prix Stock Qté
10mM (in 1mL DMSO)
96,00 $US
En stock
2mg
72,00 $US
En stock
5mg
95,00 $US
En stock
10mg
170,00 $US
En stock
50mg
595,00 $US
En stock
100mg
1 146,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SJB3-019A is a potent and novel inhibitor of USP1 with IC50 value of 0.0781 μM [1].

Ubiquitin-specific protease 1 (USP1) is a deubiquitinating (DUB) enzyme and removes polyubiquitin chains from the DNA binding 1 (ID1) protein, which plays an important role in the proliferation and progression of cancers, such as leukemia [1].

SJB3-019A is a potent and novel USP1 inhibitor. In K562 cells, SJB3-019A exhibited 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity. In HeLa cells, SJB3-019A increased the levels of Ub-PCNA and Ub-FANCD2 and reduced the homologous recombination activity [1].

Reference:
[1].  Mistry H, Hsieh G, Buhrlage SJ, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther, 2013, 12(12): 2651-2662.

Avis

Review for SJB3-019A

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SJB3-019A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.